Skip To Main Content

Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro
  • Filtros
Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery

Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery

Guidelines recommend postoperative prophylactic anticoagulation for 1-5 weeks.

Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery

Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery

Guidelines recommend postoperative prophylactic anticoagulation for 1-5 weeks.

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

Atherosclerotic Cardiovascular Disease Risk Assessment

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

Large prospective clinical trials are needed to validate the scoring threshold for pharmacoprophylaxis.

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

Large prospective clinical trials are needed to validate the scoring threshold for pharmacoprophylaxis.

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

Large prospective clinical trials are needed to validate the scoring threshold for pharmacoprophylaxis.

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

Large prospective clinical trials are needed to validate the scoring threshold for pharmacoprophylaxis.

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients

Large prospective clinical trials are needed to validate the scoring threshold for pharmacoprophylaxis.

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024